Hirokazu Hamano
Fuji Xerox
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hirokazu Hamano.
Journal of Gastroenterology and Hepatology | 2007
Masahiko Kaito; Motoh Iwasa; Naoki Fujita; Yoshinao Kobayashi; Yuji Kojima; Jiro Ikoma; Ichiro Imoto; Yukihiko Adachi; Hirokazu Hamano; Koji Yamauchi
Objectives: Lactoferrin has been reported to inhibit hepatitis C virus (HCV) infection in cultured human hepatocytes and HCV viremia in patients with chronic hepatitis C (CHC). The aim of this study was to evaluate the effect of combined triple therapy of lactoferrin, interferon and ribavirin in patients with CHC.
Cancer Science | 2015
Jiegou Xu; David B. Alexander; Masaaki Iigo; Hirokazu Hamano; Satoru Takahashi; Takako Yokoyama; Munehiro Kato; Ikuji Usami; Takeshi Tokuyama; Masahiro Tsutsumi; Mouka Tamura; Tetsuya Oguri; Akio Niimi; Yoshimitsu Hayashi; Yoshifumi Yokoyama; Ken Tonegawa; Katsumi Fukamachi; Mitsuru Futakuchi; Yuto Sakai; Masumi Suzui; Michihiro Kamijima; Naomi Hisanaga; Toyonori Omori; Dai Nakae; Akihiko Hirose; Jun Kanno; Hiroyuki Tsuda
Exposure to asbestos results in serious risk of developing lung and mesothelial diseases. Currently, there are no biomarkers that can be used to diagnose asbestos exposure. The purpose of the present study was to determine whether the levels or detection rate of chemokine (C‐C motif) ligand 3 (CCL3) in the serum are elevated in persons exposed to asbestos. The primary study group consisted of 76 healthy subjects not exposed to asbestos and 172 healthy subjects possibly exposed to asbestos. The secondary study group consisted of 535 subjects possibly exposed to asbestos and diagnosed with pleural plaque (412), benign hydrothorax (10), asbestosis (86), lung cancer (17), and malignant mesothelioma (10). All study subjects who were possibly exposed to asbestos had a certificate of asbestos exposure issued by the Japanese Ministry of Health, Labour and Welfare. For the primary study group, levels of serum CCL3 did not differ between the two groups. However, the detection rate of CCL3 in the serum of healthy subjects possibly exposed to asbestos (30.2%) was significantly higher (P < 0.001) than for the control group (6.6%). The pleural plaque, benign hydrothorax, asbestosis, and lung cancer groups had serum CCL3 levels and detection rates similar to that of healthy subjects possibly exposed to asbestos. The CCL3 chemokine was detected in the serum of 9 of the 10 patients diagnosed with malignant mesothelioma. Three of the patients with malignant mesothelioma had exceptionally high CCL3 levels. Malignant mesothelioma cells from four biopsy cases and an autopsy case were positive for CCL3, possibly identifying the source of the CCL3 in the three malignant mesothelioma patients with exceptionally high serum CCL3 levels. In conclusion, a significantly higher percentage of healthy persons possibly exposed to asbestos had detectable levels of serum CCL3 compared to healthy unexposed control subjects.
Journal of Nutritional Science and Vitaminology | 2007
Nobuo Seki; Hirokazu Hamano; Yuriko Iiyama; Yuzo Asano; Sadayuki Kokubo; Koji Yamauchi; Yoshitaka Tamura; Kazuhiro Uenishi; Hideki Kudou
Archive | 2001
Katsumi Daimon; Norihito Fukushima; Takashi Imai; Manabu Serizawa; Hirokazu Hamano; Masanori Ichimura
Archive | 2005
Noriyuki Mizutani; Hideo Maehata; Hirokazu Hamano; Hiroyuki Tanaka; Moegi Iguchi; Soichiro Kitagawa; Susumu Yoshino; Yuka Ishihara; Yosuke Tsurumi; Akira Matsumoto; Masaru Takahashi
Archive | 2007
Hirokazu Hamano
Archive | 2002
Hirokazu Hamano; Manabu Serizawa; Katsumi Daimon; Yuka Ishihara; Norihito Fukushima; Takashi Imai
Archive | 1998
Yutaka Sugizaki; Hirokazu Hamano
Archive | 2001
Manabu Serizawa; Katsumi Daimon; Norihito Fukushima; Takashi Imai; Hirokazu Hamano
Archive | 2001
Hirokazu Hamano; Katsumi Daimon; Manabu Serizawa; Norihito Fukushima; Takashi Imai; Masanori Ichimura